XML 27 R17.htm IDEA: XBRL DOCUMENT
v3.21.2

REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION | 9 Months Ended
--- | ---
Sep. 30, 2021
Concentration Risk And Geographic Information [Abstract] |
REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION | REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION The Company operates in one business segment, which primarily focuses on the development and commercialization of innovative therapies for people with serious and life-threatening rare diseases and medical conditions. The Company considers there to be revenue concentration risks for regions where Net Product Revenues exceed 10% of consolidated Net Product Revenues. The concentration of the Company’s Net Product Revenues within the regions below may have a material adverse effect on the Company’s revenues and results of operations if sales in the respective regions experience difficulties. The following table disaggregates Total Revenues from external customers and collaborative partners by geographic region. Net product revenues by geographic region are based on patient location for the Company’s commercial products, except for Aldurazyme, which is sold exclusively to Sanofi Genzyme (Genzyme) who markets and sells Aldurazyme worldwide. Aldurazyme revenues earned by the Company are included in the U.S. region as the transactions are with Genzyme, whose headquarters is located in the U.S.
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2021 |  | 2020 |  | 2021 |  | 2020
Total revenues by geographic region: |  |  |  |  |  |  |
United States | $ | 196,239 |  |  | $ | 252,948 |  |  | $ | 608,670 |  |  | $ | 729,672 |
Europe | 115,497 |  |  | 121,158 |  |  | 450,016 |  |  | 375,453 |
Latin America | 38,958 |  |  | 44,064 |  |  | 140,911 |  |  | 141,852 |
Rest of world | 58,048 |  |  | 58,614 |  |  | 196,868 |  |  | 161,361 |
Total revenues | $ | 408,742 |  |  | $ | 476,784 |  |  | $ | 1,396,465 |  |  | $ | 1,408,338 |
The following table disaggregates total Net Product Revenues by product.
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2021 |  | 2020 |  | 2021 |  | 2020
Net product revenues by product: |  |  |  |  |  |  |
Vimizim | $ | 136,744 |  |  | $ | 147,891 |  |  | $ | 466,697 |  |  | $ | 401,789 |
Naglazyme | 71,172 |  |  | 76,323 |  |  | 297,321 |  |  | 271,585 |
Kuvan | 67,687 |  |  | 123,993 |  |  | 217,257 |  |  | 368,604 |
Palynziq | 60,729 |  |  | 46,092 |  |  | 173,702 |  |  | 121,354 |
Brineura | 32,984 |  |  | 25,455 |  |  | 90,641 |  |  | 75,223 |
Voxzogo | 144 |  |  | — |  |  | 144 |  |  | — |
Firdapse | — |  |  | — |  |  | — |  |  | 1,316 |
Total net product revenues marketed by the Company | $ | 369,460 |  |  | $ | 419,754 |  |  | $ | 1,245,762 |  |  | $ | 1,239,871 |
Aldurazyme net product revenues marketed by Genzyme | 24,380 |  |  | 40,987 |  |  | $ | 102,517 |  |  | $ | 128,945 |
Total net product revenues | $ | 393,840 |  |  | $ | 460,741 |  |  | $ | 1,348,279 |  |  | $ | 1,368,816 |
The table below disaggregates total Net Product Revenues based on patient location for products sold directly by the Company, and global sales of Aldurazyme, which is marketed by Genzyme.
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2021 |  | 2020 |  | 2021 |  | 2020
United States | $ | 166,554 |  |  | $ | 203,892 |  |  | $ | 491,028 |  |  | $ | 582,734 |
Europe | 108,568 |  |  | 115,548 |  |  | 424,144 |  |  | 360,718 |
Latin America | 38,958 |  |  | 44,064 |  |  | 140,911 |  |  | 141,852 |
Rest of world | 55,380 |  |  | 56,250 |  |  | 189,679 |  |  | 154,567 |
Total net product revenues marketed by the Company | $ | 369,460 |  |  | $ | 419,754 |  |  | $ | 1,245,762 |  |  | $ | 1,239,871 |
Aldurazyme net product revenues marketed by Genzyme | 24,380 |  |  | 40,987 |  |  | 102,517 |  |  | 128,945 |
Total net product revenues | $ | 393,840 |  |  | $ | 460,741 |  |  | $ | 1,348,279 |  |  | $ | 1,368,816 |
The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented.
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2021 |  | 2020 |  | 2021 |  | 2020
Customer A | 20 | % |  | 16 | % |  | 17 | % |  | 15 | %
Customer B | 16 | % |  | 14 | % |  | 14 | % |  | 14 | %
Customer C | 11 | % |  | 11 | % |  | 10 | % |  | 12 | %
Total | 47 | % |  | 41 | % |  | 41 | % |  | 41 | %
On a consolidated basis, two customers accounted for 31% and 14% of the Company’s September 30, 2021 accounts receivable balance, respectively, compared to December 31, 2020, when two customers accounted for 24% and 22% of the accounts receivable balance, respectively. As of September 30, 2021, and December 31, 2020, the accounts receivable balance for Genzyme included $83.9 million and $72.1 million, respectively, of unbilled accounts receivable, which becomes payable to the Company when the product is sold through by Genzyme. The Company does not require collateral from its customers, but does perform periodic credit evaluations of its customers’ financial condition and requires prepayments in certain circumstances. The COVID-19 pandemic continues to affect economies and business around the world. The Company’s global revenue sources, mostly in the form of demand interruptions such as missed patient infusions and delayed treatment starts for new patients, and its business operations were impacted by the COVID-19 pandemic during the nine months ended September 30, 2021 and 2020, and the Company anticipates a continued impact due to COVID-19 on its financial results in the remainder of 2021. The extent and duration of such effects remain uncertain and difficult to predict, particularly as virus variants continue to spread. The Company is actively monitoring and managing its response and assessing actual and potential impacts to its operating results and financial condition, as well as developments in its business, which could further impact developments, trends and expectations. See the risk factor related to the impact of the coronavirus pandemic, “The COVID-19 pandemic could continue to materially adversely affect our business, results of operations and financial condition.” described in “Risk Factors” in Part II, Item 1A of this Quarterly Report, for additional details on the impact of the COVID-19 pandemic. The Company is mindful that conditions in the current macroeconomic environment could affect the Company’s ability to achieve its goals. The Company sells its products in countries that face economic volatility and weakness. Although the Company has historically collected receivables from customers in certain countries, sustained weakness or further deterioration of the local economies and currencies and effects of the impact of the ongoing COVID-19 pandemic may cause customers in those countries to delay payment or be unable to pay for the Company’s products. The Company believes that the allowances for doubtful accounts related to these countries, if any, are adequate based on its analysis of the specific business circumstances and expectations of collection for each of the underlying accounts in these countries. The Company will continue to monitor these conditions and will attempt to adjust its business processes, as appropriate, to mitigate macroeconomic risks to its business.

X
- Definition Concentration risk and geographic information. + References No definition available. + Details
Name: | bmrn_ConcentrationRiskAndGeographicInformationAbstract
Namespace Prefix: | bmrn_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Concentration risk and segment reporting disclosure. + References No definition available. + Details
Name: | bmrn_ConcentrationRiskAndSegmentReportingDisclosureTextBlock
Namespace Prefix: | bmrn_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration